Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

Bortezomib, an inhibitor of proteasomes (sites of protein degradation in cells), has activity against advanced multiple myeloma. This study compared bortezomib with high-dose dexamethasone relatively soon after a relapse of multiple myeloma had occurred with other treatments. Bortezomib was superior...

Full description

Bibliographic Details

Main Authors:	Richardson, Paul G. (Author) , Sonneveld, Pieter (Author) , Schuster, Michael W. (Author) , Irwin, David (Author) , Stadtmauer, Edward A. (Author) , Facon, Thierry (Author) , Harousseau, Jean-Luc (Author) , Ben-Yehuda, Dina (Author) , Lonial, Sagar (Author) , Goldschmidt, Hartmut (Author) , Reece, Donna (Author) , San-Miguel, Jesus F. (Author) , Bladé, Joan (Author) , Boccadoro, Mario (Author) , Cavenagh, Jamie (Author) , Dalton, William S. (Author) , Boral, Anthony L. (Author) , Esseltine, Dixie L. (Author) , Porter, Jane B. (Author) , Schenkein, David (Author) , Anderson, Kenneth C. (Author)
Format:	Article (Journal)
Language:	English
Published:	June 16, 2005
In:	The New England journal of medicine Year: 2005, Volume: 352, Issue: 24, Pages: 2487-2498
ISSN:	1533-4406
DOI:	10.1056/NEJMoa043445
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1056/NEJMoa043445
Author Notes:	Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster, David Irwin, Edward A. Stadtmauer, Thierry Facon, Jean-Luc Harousseau, Dina Ben-Yehuda, Sagar Lonial, Hartmut Goldschmidt, Donna Reece, Jesus F. San-Miguel, Joan Bladé, Mario Boccadoro, Jamie Cavenagh, William S. Dalton, Anthony L. Boral, Dixie L. Esseltine, Jane B. Porter, David Schenkein, and Kenneth C. Anderson for the Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigator